SCOTTSDALE, AZ--(MARKET WIRE)--Oct 25, 2007 -- Health Enhancement Products, Inc. (OTC BB:HEPI.OB - News) announced today that they have received preliminary, independent results of the clinical lot of ProAlgaZyme that was used in the recently suspended clinical trial. The test was designed to detect potential degradation of the active protein components in ProAlgaZyme. Dr. Michael Tempesta, who has been appointed as Chairman of the Scientific Advisory Board and has worked with HEPI for several years stated: "The original clinical product, which had not been frozen, was tested and showed the presence of active protein. However, in the same tests, all the returned clinical samples that had been frozen showed clear signs of loss of active protein. This is an indication that the frozen product received for the trials was rendered inactive, and would not be expected to produce a measurable effect on the patients." Dr. Tempesta also stated that, "Additional tests are underway, and the results will be announced once they are completed. New labeling will now include a warning to not freeze the product."

About Health Enhancement Products, Inc. and ProAlgaZyme

Health Enhancement Products, Inc. is a nutraceutical company engaged in the development of a Dietary Supplement product using only pure, all-natural ingredients. The company's sole product is ProAlgaZyme, a liquid product produced from algae grown in 100% distilled water. The liquid in which the algae are grown is drawn off, filtered, tested and bottled as ProAlgaZyme. HEPI Pharmaceuticals, Inc. is exploring the development of the potential pharmaceutical applications of ProAlgaZyme.

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, our inability to obtain regulatory approvals necessary to market and sell PAZ as a pharmaceutical, and the company's ability to secure funding, including for the subsidiary's pharmaceutical development of PAZ. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

For more information, please visit www.heponline.com.